Boston Medical CenterBoston, MA
72 - Real World Outcomes of Upadacitinib Compared to Risankizumab as Second-Line Therapy in Patients With Crohn’s Disease Exposed to Tumor Necrosis Factor-Alpha Inhibitors
Wednesday, October 29, 20259:40 AM - 9:50 AM PDT